[go: up one dir, main page]

AU2001236042A1 - Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell - Google Patents

Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell

Info

Publication number
AU2001236042A1
AU2001236042A1 AU2001236042A AU2001236042A AU2001236042A1 AU 2001236042 A1 AU2001236042 A1 AU 2001236042A1 AU 2001236042 A AU2001236042 A AU 2001236042A AU 2001236042 A AU2001236042 A AU 2001236042A AU 2001236042 A1 AU2001236042 A1 AU 2001236042A1
Authority
AU
Australia
Prior art keywords
cell
culture
vaccine
serum
usable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001236042A
Other versions
AU2001236042B9 (en
AU2001236042B2 (en
Inventor
Yoichiro Kino
Keiichi Makizumi
Kanako Masuda
Sachio Tokiyoshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Priority claimed from PCT/JP2001/001599 external-priority patent/WO2001064846A1/en
Publication of AU2001236042A1 publication Critical patent/AU2001236042A1/en
Application granted granted Critical
Publication of AU2001236042B2 publication Critical patent/AU2001236042B2/en
Publication of AU2001236042B9 publication Critical patent/AU2001236042B9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2001236042A 2000-03-03 2001-03-02 Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell Ceased AU2001236042B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-59262 2000-03-03
JP2000059262 2000-03-03
PCT/JP2001/001599 WO2001064846A1 (en) 2000-03-03 2001-03-02 Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell

Publications (3)

Publication Number Publication Date
AU2001236042A1 true AU2001236042A1 (en) 2001-11-22
AU2001236042B2 AU2001236042B2 (en) 2006-01-12
AU2001236042B9 AU2001236042B9 (en) 2006-06-29

Family

ID=18579742

Family Applications (2)

Application Number Title Priority Date Filing Date
AU3604201A Pending AU3604201A (en) 2000-03-03 2001-03-02 Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
AU2001236042A Ceased AU2001236042B9 (en) 2000-03-03 2001-03-02 Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU3604201A Pending AU3604201A (en) 2000-03-03 2001-03-02 Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell

Country Status (9)

Country Link
US (1) US6825036B2 (en)
EP (1) EP1260581B1 (en)
JP (1) JP4698112B2 (en)
KR (1) KR100797547B1 (en)
AT (1) ATE473272T1 (en)
AU (2) AU3604201A (en)
CA (1) CA2401117C (en)
DE (1) DE60142506D1 (en)
WO (1) WO2001064846A1 (en)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10144906B4 (en) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Process for the large-scale production of vaccines
DE10144903A1 (en) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Replication of virus in cell cultures, useful for preparing vaccines and diagnostic reagents, where replication of cells and virus is simultaneous
CN101189326B (en) * 2004-12-23 2013-06-12 米迪缪尼有限公司 Non-tumorigenic MDCK cell line for viral propagation
CA2601006C (en) * 2005-03-10 2012-10-23 Kyoritsu Seiyaku Corporation Cell strain capable of being cultured without ingredients derived from animals, method of producing the same, method of producing virus using the same, and method of producing vaccine
FR2884255B1 (en) 2005-04-11 2010-11-05 Vivalis USE OF EBX AVIATION STEM CELL LINES FOR THE PRODUCTION OF INFLUENZA VACCINE
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
CN101365480B (en) 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 Cell-derived virus vaccines with reduced residual cellular DNA levels via β-propiolactone treatment
WO2007052058A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EA014028B1 (en) 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
HUE051122T2 (en) 2005-11-04 2021-03-01 Seqirus Uk Ltd Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
HUE049580T2 (en) 2006-01-27 2020-09-28 Seqirus Uk Ltd Influenza vaccines containing hemagglutinin and matrix proteins
CN101448523A (en) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 Storage of influenza vaccines without refrigeration
WO2007126810A2 (en) 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
EP2022849A4 (en) * 2006-05-11 2010-10-06 Chemo Sero Therapeut Res Inst Method for proliferation of influenza virus
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP4585610A3 (en) 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
EP2069480B1 (en) * 2006-09-15 2014-03-19 MedImmune, LLC Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
PL2121011T3 (en) 2006-12-06 2014-10-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
CN101784283A (en) 2007-06-27 2010-07-21 诺华有限公司 Low-additive influenza vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8685654B2 (en) 2007-12-24 2014-04-01 Novartis Ag Assays for adsorbed influenza vaccines
EA201071086A1 (en) 2008-03-18 2011-04-29 Новартис Аг ADVANCED METHOD FOR OBTAINING VACCINE ANTIGENS OF THE VIRUS VIRUS
TW201012930A (en) * 2008-06-16 2010-04-01 Intervet Int Bv Method of replicating viruses in suspension
MY172788A (en) 2008-08-01 2019-12-12 Gamma Vaccines Pty Ltd Influenza vaccines
CN103952376A (en) 2008-09-24 2014-07-30 米迪缪尼有限公司 Methods for cultivating cells, propagating and purifying viruses
EP2396031A1 (en) 2009-02-10 2011-12-21 Novartis AG Influenza vaccines with increased amounts of h3 antigen
US20120093859A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
EP3173097A3 (en) 2009-02-10 2017-07-12 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
CN102548577A (en) 2009-04-27 2012-07-04 诺华有限公司 Adjuvanted vaccines for protecting against influenza
CN102803515A (en) 2009-05-08 2012-11-28 诺华有限公司 Generic Assays For Detection Of Influenza Viruses
ES2394797T3 (en) 2009-05-21 2013-02-05 Novartis Ag Reverse genetics using non-endogenous pol l promoters
AU2010277310B2 (en) 2009-07-31 2015-01-15 Seqirus UK Limited Reverse genetics systems
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
JP5871806B2 (en) 2009-10-20 2016-03-01 ノバルティス アーゲー Improved reverse genetics for virus rescue
WO2011056591A1 (en) 2009-10-26 2011-05-12 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
AU2011225748A1 (en) 2010-03-08 2012-09-13 Novartis Ag Methods of testing for intracellular pathogens
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP2566323A2 (en) 2010-05-06 2013-03-13 Novartis AG Organic peroxide compounds for microorganism inactivation
EP2571520B1 (en) 2010-05-21 2018-04-04 Seqirus UK Limited Influenza virus reassortment method
AU2011262309B2 (en) 2010-06-01 2015-08-13 Seqirus UK Limited Concentration of influenza vaccine antigens without lyophilization
AU2011262312B2 (en) 2010-06-01 2015-05-28 Novartis Ag Concentration and lyophilization of influenza vaccine antigens
US9517205B2 (en) 2010-08-20 2016-12-13 Seqirus UK Limited Soluble needle arrays for delivery of influenza vaccines
WO2012033236A1 (en) * 2010-09-06 2012-03-15 에스케이케미칼 주식회사 Mdck cell line adapted to serum-free culture and suspension culture, and method for preparing viruses for vaccine using cells thereof
EP3012330A1 (en) 2010-09-07 2016-04-27 Novartis AG Generic assays for detection of mammalian reovirus
US20140079732A1 (en) 2011-01-27 2014-03-20 Gamma Vaccines Pty Limited Combination vaccines
JP2014527799A (en) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション Influenza virus as a live attenuated vaccine having a mutant PB2 gene segment
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
WO2013057715A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
US20140335507A1 (en) 2011-12-12 2014-11-13 Novartis Ag Assays for influenza virus hemagglutinins
ES2628301T3 (en) 2012-03-02 2017-08-02 Seqirus UK Limited Recombination of influenza virus
HK1208502A1 (en) 2012-06-04 2016-03-04 Novartis Ag Improved safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
EP2925356A2 (en) 2012-12-03 2015-10-07 Novartis AG Reassortant influenza a viren
CN103045530B (en) * 2012-12-14 2015-06-17 山东滨州沃华生物工程有限公司 Method for suspension culturing cell
UA121193C2 (en) * 2012-12-28 2020-04-27 Бьорінгер Інгельхайм Ветмедіка Гмбх METHOD OF OBTAINING IMMUNOGENIC COMPOSITION AGAINST MYCOPLASMA
US9878027B2 (en) 2012-12-28 2018-01-30 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
US10232031B2 (en) 2013-03-13 2019-03-19 Seqirus UK Limited Influenza virus reassortment
WO2014180999A1 (en) 2013-05-10 2014-11-13 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
DE202013005130U1 (en) 2013-06-05 2013-09-10 Novartis Ag Influenza virus reassortment
DE202013005100U1 (en) 2013-06-05 2013-08-26 Novartis Ag Influenza virus reassortment
BR112015030582A2 (en) 2013-06-06 2017-08-29 Novartis Ag CHIMERIC INFLUENZA HEMAGGLUTININ AND CHIMERIC NEURAMINIDASE SEGMENT, CHIMERIC HEMAGGLUTININ PROTEIN, RE-ARRANGEMENT INFLUENZA VIRUS, METHODS FOR PREPARING A RE-ARRANGEMENT INFLUENZA VIRUS AND FOR PREPARING A VACCINE AND EXPRESSION SYSTEM
KR101370512B1 (en) 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 Mdck-derived cell lines suspension-cultured in a protein-free medium and method for propagating virus using the same
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
BR112017028011A2 (en) 2015-06-26 2018-08-28 Seqirus Uk Ltd antigenically matched influenza vaccines
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
CN108027371B (en) 2015-07-07 2020-08-18 思齐乐 Influenza Efficacy Test
WO2017072744A1 (en) 2015-10-30 2017-05-04 National Institute Of Infectious Diseases And Vaccinology, National Health Research Institutes Mdck suspension cell lines in serum-free, chemically-defined media for vaccine production
CN105567628B (en) * 2016-01-30 2019-07-12 令世鑫 A kind of low blood serum medium of the full culture mdck cell that suspends
WO2017143236A1 (en) 2016-02-19 2017-08-24 Yoshihiro Kawaoka Improved influenza b virus replication for vaccine development
KR102453351B1 (en) * 2017-07-05 2022-10-07 에스케이바이오사이언스(주) Method for manufacture of Influenza Working Virus Seed Stock
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
CN108265024B (en) * 2018-03-30 2022-02-18 吉林冠界生物技术有限公司 Serum-free medium suitable for MDCK cell full-suspension culture and preparation method thereof
JP7783047B2 (en) 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション Recombinant biologically contained filovirus vaccines
JP7655849B2 (en) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション Vectors for eliciting immune responses against non-dominant epitopes within the hemagglutinin (HA) protein
CN109609436A (en) * 2018-11-09 2019-04-12 中农威特生物科技股份有限公司 A kind of no CO2The preparation method of the mdck cell of environment suspension serum-free cell system entirely
CA3123504A1 (en) 2018-12-21 2020-06-25 Intervet International B.V. Serum free intracellular pathogen vaccine
JP2022527235A (en) 2019-01-23 2022-06-01 義裕 河岡 Mutations that impart genetic stability to additional genes in influenza virus
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
MX2022006005A (en) 2019-11-18 2022-10-27 Seqirus Pty Ltd Method for producing reassortant influenza viruses.
JP2023511444A (en) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション Recombinant influenza virus with stabilized NA
KR20220152226A (en) * 2020-02-11 2022-11-15 사이토누스 테라퓨틱스, 인크. Rapid Vaccine Platform
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
CA3183701A1 (en) * 2020-06-22 2021-12-30 Sung Jin Kim Method for large scale-production of vaccinia virus using suspension cells
CN114317405B (en) * 2021-12-21 2023-08-29 广东省华晟生物技术有限公司 Serum-free full-suspension culture type F81 cell line and construction method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348877A (en) * 1993-03-12 1994-09-20 Boyce Thompson Institute For Plant Research, Inc. Method of adapting anchorage-dependent cell lines to suspension conditions
FR2726574B1 (en) * 1994-11-04 1997-01-17 Univ Paris Curie PROCESS FOR DISSOCIATION OF EUKARYOTIC CELLS IN CULTURE
ES2323490T3 (en) * 1994-11-10 2009-07-17 Baxter Healthcare Sa PROCEDURE OF PRODUCTION OF BIOLOGICAL AGENTS IN A CROP MEANS WITHOUT PROTEINS.
DE19612966B4 (en) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK cells and methods of propagating influenza viruses
DE19612967A1 (en) 1996-04-01 1997-10-02 Behringwerke Ag Process for the propagation of influenza viruses in cell culture, and the influenza viruses obtainable by the process

Similar Documents

Publication Publication Date Title
AU2001236042A1 (en) Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
AU2722997A (en) Influenza virus replicated in mammalian cell culture and vaccine production
WO2003091401A3 (en) Multi plasmid system for the production of influenza virus
IL161858A0 (en) Cell culture process
AU2002336930A1 (en) Method for producing isolated cell cultures, culture medium for cultivating cell cultures and cell culture
AU2002225781A1 (en) Microincubator cell culture apparatus including transparent heater
HUP0203386A3 (en) Magnetic glass particles, method for their preparation and uses thereof
AU2002225681A1 (en) Yeast-dentritic cell vaccines and uses thereof
AU2001294577A1 (en) Methods for preparing interferon producing dentitric cells
AU2002221033A1 (en) Cells to be used in producing virus vector, process for producing the same and process for producing virus vector with the use of the cells
AU2001280149A1 (en) Stem cell culture medium and culture method by using the same
AU2001269445A1 (en) Method of culturing zooplankton, apparatus for culturing by the same, and culture obtained by the same
AU2002221526A1 (en) Method for producing vital, biological substitute tissue in vitro using cell cultures and a support
AU2001234616A1 (en) Vaccine composition, process and methods
AU4771600A (en) Cells, culture methods and their uses
AU2001252591A1 (en) Novel promoters and gene expression method by using the promoters
GB2397819B (en) (R)-Hydroxycarboxylic acid producing recombinant microorganism and process for preparing (R)-hydroxycarboxylic acid using the same
AU2001254864A1 (en) Cell culture method, cell cluster obtained by said methods and use thereof
AU7456101A (en) Process for producing hexafluoroethane and use thereof
AU2001277742A1 (en) Solid culture medium and method for preparing the same
AU2001242750A1 (en) Novel protein, process for producing the same and use thereof
AU3673500A (en) Fine particles targeting cells and process for producing the same
AU2003260593A1 (en) Method for culturing hvc virus in vitro
AU2002323824A1 (en) The intact hepatitis c virus and the method for culturing it in a vitro cell culture
AU2001277067A1 (en) Papillomavirus infected epithelial cells and methods of producing infectious papillomavirus in epithelial cells and uses thereof